Novavax Stock News

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, trea

Throughout the history of financial markets, there is ample evidence of irrational investor behavior leading to euphoria. Be it the Tulip Mania of 1634 or the Housing Bubble and the subsequent financi

Novavax has reported both positive and negative news in recent days, sending the shares higher, then lower. The company settled a dispute with a key customer, but quarterly earnings missed analysts' e

In 2022, Novavax canceled a purchase agreement with Gavi, leading to a dispute over $700 million in advance payments. A settlement has been reached, and Novavax may only pay up to $475 million back to

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Novavax, Inc. (NASDAQ:NVAX) shares fell over 27% on Wednesday as the Covid-19 vaccine maker warned of slowing sales ahead after missing earnings expectations in the final quarter. Revenue for the thre

The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim

Novavax Inc (NASDAQ:NVAX) missed  top- and bottom-line estimates  for the fourth quarter.

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company's earnings report for the fourth quarter of 2024. Let's dig into everything that has investors in NVA

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago.

Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.

Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.

Novavax fell behind in the coronavirus vaccine race, which has weighed heavily on its earnings potential and share price. The company is working to recover and spur growth down the road.

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th

Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi'